The pharmaceutical company Allergan is the target of a qui tam case unsealed this week in federal court in Philadelphia.
The company—which produces Botox, its most well-known drug, as well as eye care medicines including Restasis—is alleged to have built an elaborate kickback scheme to induce ophthalmologists to prescribe its eye products, according to the complaint.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
